文献速递肝病消化道肿瘤与早癌

THCC-RI在HCC早期检测策略研究中的外部验证

Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-02-09

本研究在美国7中心前瞻性肝硬化队列(HEDS研究,1560例,5051人年)中外部验证THCC-RI。中位随访2.5年,114例发生HCC;THCC-RI的C-index为0.77,1、3、5年AUC分别为0.77、0.73、0.71,校准良好;高危组(9-10分位)HCC风险是中危组(3-8分位)的3.5倍(HR=3.5,95%CI 2.4-5.1)。

要点

  • THCC-RI在独立多中心肝硬化队列中表现出良好的HCC风险预测效能,C-index为0.77。
  • THCC-RI高危组(9-10分位)HCC风险是 medium 危组(3-8分位)的3.5倍(HR=3.5,95%CI 2.4-5.1)。
  • THCC-RI在5年随访内判别力和校准稳定,3年后AUC下降幅度小于aMAP评分。

核心结论

  • THCC-RI在独立多中心肝硬化队列中预测HCC风险表现良好,5年随访内判别力与校准稳定,但融入临床路径仍需进一步研究。

研究设计与样本

  • 前瞻性队列外部验证研究,使用HCC早期检测策略(HEDS)研究数据,纳入美国7中心接受规律HCC监测的肝硬化患者1560例,共5051人年随访。

主要发现

  • 中位随访2.5年,114例患者发生HCC。
  • THCC-RI的C-index为0.77(95%CI 0.64-0.85),1年AUC为0.77(95%CI 0.65-0.85),3年AUC为0.73(95%CI 0.66-0.79),5年AUC为0.71(95%CI 0.65-0.77)。
  • THCC-RI校准良好,观察风险与预测风险一致性佳。
  • 高危组(9、10分位)HCC风险是 medium 危组(3-8分位)的3.5倍(HR=3.5,95%CI 2.4-5.1)。
  • THCC-RI在随访前2年判别力与aMAP评分相似,但超过3年后aMAP的AUC下降幅度大于THCC-RI。

临床怎么用

  • THCC-RI可用于肝硬化患者HCC风险分层,高危组(9-10分位)风险显著升高,或可辅助制定监测策略;但融入临床路径仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We previously developed a hepatocellular carcinoma (HCC) risk stratification model, the Texas HCC Consortium Risk Index (THCC-RI), for patients with cirrhosis. In this cohort study, we aimed to externally validate THCC-RI in a prospective cohort of patients with cirrhosis. METHODS: We used data from the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study, a prospective cohort of patients with cirrhosis enrolled in regular HCC surveillance at 7 centers in the United States. Patients were followed from enrollment until HCC diagnosis, liver transplantation, death, or December 2023. RESULTS: The analysis was conducted in 1560 patients who contributed a total of 5051 person-years of follow-up (mean age, 59 years; 47% women; 40% with hepatitis C; 16% alcohol-associated disease; and 22% metabolic dysfunction-associated steatotic liver disease). Over a median follow-up of 2.5 years, 114 patients developed HCC. The THCC-RI had a C-index of 0.77 (95% confidence interval [CI], 0.64-0.85), with area under the receiver operating characteristic curve estimates of 0.77 (95% CI, 0.65-0.85) at 1 year, 0.73 (95% CI, 0.66-0.79) at 3 years, and 0.71 (95% CI, 0.65-0.77) at 5 years. THCC-RI was well-calibrated, with good agreement between observed and predicted risk. Compared with the medium-risk group (deciles 3-8), the high-risk group (deciles 9, 10) had 3.5-fold (hazard ratio, 3.5; 95% CI, 2.4-5.1) higher risk of HCC. THCC-RI had similar discrimination as the Age, Male, Albumin-bilirubin, and Platelets (aMAP) score during the first 2 years of follow-up, but the areas under the receiver operating characteristic curve for aMAP dropped more than those for THCC-RI as the time horizon expanded beyond 3 years. CONCLUSIONS: In an independent multi-center cohort, THCC-RI had good performance for predicting the future risk of HCC in patients with cirrhosis, with stable discrimination and calibration over a 5-year follow-up. Implementation of THCC-RI into clinical care pathways requires further research.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Lopez C, Ning J, et al. Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clin Gastroenterol Hepatol. 2026. PMID: 41672261. doi:10.1016/j.cgh.2026.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。